Skip to main content
Displaying 13 - 24 of 29
Display:
12
24
48
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: Unfolding the metabolic dysfunction of MASH: exploring the pathophysiology and outcomes - EASL Congress 2024
View
Metabolism, Alcohol & Toxicity
6
Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022
View
Metabolism, Alcohol & Toxicity
6
Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022
View
Metabolism, Alcohol & Toxicity
6
Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022
View
Metabolism, Alcohol & Toxicity
6
Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022
View
Metabolism, Alcohol & Toxicity
6
Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022
View
Metabolism, Alcohol & Toxicity
6
Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021
View
Pagination
First page
« First
Previous page
‹ previous
Page
1
Current page
2
Page
3
Next page
next ›
Last page
Last »
©2019 - EASL. All Rights Reserved. Powered by
Enovation
.
Footer menu
Content Access policy
Privacy Policy
Cookie Policy